Psilocybin Microdosing on Cognition, Mood and Quality of Life

Summary

This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.

Timeline

Start

2026-08-10

Primary completion

2028-04-01

Completion

2028-04-01

Drugs

Indications

No indication recorded.